• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Redfield Robert

    4/3/24 7:55:26 PM ET
    $ONTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ONTX alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Redfield Robert

    (Last) (First) (Middle)
    12 PENNS TRAIL

    (Street)
    NEWTOWN PA 18940

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    04/01/2024
    3. Issuer Name and Ticker or Trading Symbol
    Traws Pharma, Inc. [ TRAW ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Acting Chief Medical Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Robert Redfield 04/03/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ONTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ONTX

    DatePrice TargetRatingAnalyst
    3/1/2022$7.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $ONTX
    SEC Filings

    See more
    • SEC Form 10-K/A filed by Onconova Therapeutics Inc. (Amendment)

      10-K/A - Traws Pharma, Inc. (0001130598) (Filer)

      4/29/24 4:06:03 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form D filed by Onconova Therapeutics Inc.

      D - Traws Pharma, Inc. (0001130598) (Filer)

      4/16/24 4:15:33 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Onconova Therapeutics Inc.

      DEFA14A - Traws Pharma, Inc. (0001130598) (Filer)

      4/16/24 4:09:29 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ladenburg Thalmann initiated coverage on Onconova Therapeutics with a new price target

      Ladenburg Thalmann initiated coverage of Onconova Therapeutics with a rating of Buy and set a new price target of $7.00

      3/1/22 7:21:18 AM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Onconova Therapeutics with a new price target

      Guggenheim initiated coverage of Onconova Therapeutics with a rating of Buy and set a new price target of $4.00

      5/18/21 6:31:16 AM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Traws Pharma Announces New Employee Inducement Grants

      NEWTOWN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW, "Traws", the "Company"))) today announced it has granted equity awards to new employees who joined Traws in connection with the recent acquisition of Trawsfynydd Therapeutics, Inc. by Onconova Therapeutics, Inc. (the "Merger"). On April 1, 2024, Traws granted restricted stock equity awards to Werner Cautreels, Iain Dukes, Nikolay Savchuk, C. David Pauza and Robert Redfield, as an inducement for each of them to accept employment, which equity awards relate to, 200,000, 67,500, 67,500, 97,500 and 97,500 shares of Traws common stock. One-quarter (1/4) of the shares subject to each restricted stock equity awar

      4/2/24 7:15:00 AM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company

      Closing cash balance of approximately $28 million expected from concurrent private placement led by OrbiMed and Torrey PinesFunding expected to advance development of three potential best-in-class/class leading assets: viroksavir, a cap-dependent endonuclease inhibitor for influenza; travaltrelvir, a protease inhibitor for COVID19; and narazaciclib, a next generation CDK4/6 inhibitor for low grade endometriod endometrial cancer (LGEEC)Multiple near-term catalysts, for viroksavir and travaltrevir in 2024, with first top-line read-outs expected in H2 2024Traws Pharma to be led by incoming CEO, Werner Cautreels, Ph.D. Combined board to be led by Executive Chairman Iain Dukes DPhil (OrbiMed) alo

      4/2/24 7:00:00 AM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024

      NEWTOWN, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will present an abstract related to preclinical studies conducted by the Company and its collaborators to further characterize the mechanism of rigosertib at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024), taking place April 5-10, 2024 in San Diego, CA. "The ability to impact multiple targets is an important characteristic of Onconova's two lead clinical programs, rigosertib and naraz

      3/8/24 8:00:00 AM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONTX
    Financials

    Live finance-specific insights

    See more
    • Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

      Narazaciclib progressing towards registrational studies; target engagement and acceptable safety profile support further dose escalation, affirming differentiated profile Update on the registrational preparations for the narazaciclib program and the rigosertib trial plan expected in the first half of 2024 Company to host conference call and webcast at 4:30 p.m. ET on Tuesday, November 14, 2023 NEWTOWN, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today reported third quarter 2023 financial results a

      11/14/23 4:05:00 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

      NEWTOWN, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to release its third quarter 2023 financial results on Tuesday, November 14, 2023. Management plans to host a conference call and live webcast at 4:30 p.m. ET on the same day to discuss these results and provide an update on its pipeline programs. Conference Call and Webcast Information Interested parties who wish to participate in the conference call may do so by dialing: (800) 715-9871 for domestic or(646

      11/7/23 4:05:00 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics Reports Corporate Update and Announces Second Quarter 2023 Financial Results

      Anticipate topline results from the Phase 1 monotherapy and Phase 1/2 combination study with letrozole in Q4 2023 Plans are underway for a registrational trial with rigosertib in patients with RDEB-associated squamous cell carcinoma based on a constructive Type B FDA meeting held in June Company to host conference call and webcast at 4:30 p.m. ET on Thursday, August 10, 2023 NEWTOWN, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today reported second quarter 2023 financial results a

      8/10/23 4:05:00 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Orbimed Advisors Llc claimed ownership of 1,045,261 shares (SEC Form 3) (Amendment)

      3/A - Traws Pharma, Inc. (0001130598) (Issuer)

      4/12/24 4:11:22 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Tpav, Llc claimed ownership of 1,222,738 shares (SEC Form 3) (Amendment)

      3/A - Traws Pharma, Inc. (0001130598) (Issuer)

      4/11/24 5:41:38 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Redfield Robert was granted 97,500 shares (SEC Form 4)

      4 - Traws Pharma, Inc. (0001130598) (Issuer)

      4/3/24 8:07:09 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Onconova Expands Leadership Team with Two Key Appointments

      Dr. Victor Moyo named Chief Medical OfficerMeena Arora joins as Vice President Global Medical Affairs and R&D NEWTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova", the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company expanded its leadership team with the naming of Dr. Victor Moyo as Chief Medical Officer (CMO), and the addition of Meena Arora as Vice President, Global Medical Affairs and Research and Development (R&D). "We are delighted to have Dr. Moyo and Ms. Arora as integral members of our team at Onconova as we prepar

      10/24/23 8:00:00 AM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics Appoints Drs. Peter Atadja and Trafford Clarke to its Board of Directors

      NEWTOWN, Pa., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the appointments of Peter Atadja, Ph.D., and Trafford Clarke, Ph.D., as independent members of the Company's Board of Directors. "It is my pleasure to welcome Peter and Trafford to our Board," said Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova. "Their track record of successfully building and leading teams tasked with the discovery, development, and delivery of novel therapies is impressive. I look forward to benefiti

      12/19/22 4:05:23 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Onconova Therapeutics Appoints Adar Makovski Silverstein, Ph.D., as Director, Corporate Development

      NEWTOWN, Pa., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Dr. Adar Makovski Silverstein has joined Onconova as Director, Corporate Development. "Adar's deep scientific expertise in oncology and business development experience at leading biotechnology companies, most recently at Amgen, make her an excellent addition to our team at Onconova," said Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova. "We are thrilled to have her join us and look forward to benefitting from her insights. Her str

      12/13/21 8:00:00 AM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Onconova Therapeutics Inc.

      SC 13D - Traws Pharma, Inc. (0001130598) (Subject)

      4/8/24 9:37:11 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Onconova Therapeutics Inc. (Amendment)

      SC 13G/A - Onconova Therapeutics, Inc. (0001130598) (Subject)

      2/14/22 3:20:33 PM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Onconova Therapeutics, Inc.

      SC 13G - Onconova Therapeutics, Inc. (0001130598) (Subject)

      10/1/21 11:01:51 AM ET
      $ONTX
      Biotechnology: Pharmaceutical Preparations
      Health Care